To evaluate the effect of amyR on the AD-related burden, in terms of p-tau/Aβ42 ratio, we applied Pearson’s chi-squared test to A + T − patients and found a different distribution of pathological p-tau/Aβ42 levels between CSFAβ42 + /amyR − and CSFAβ42 + /amyR + subgroups [cut-off ≥ 0.086: 35.7% vs 78%, χ2 (1, n = 105) = 27.018, p < 0.001; cut-off ≥ 0.122: 17.3% vs 63%, χ2 (1, n = 105) = 21.506, p < 0.001]. The gene discussed is MAPT; the disease is Alzheimer disease.